Barclays Reaffirms Equal Weight Rating for ICON Public (NASDAQ:ICLR)

ICON Public (NASDAQ:ICLR)‘s stock had its “equal weight” rating restated by equities research analysts at Barclays in a research report issued to clients and investors on Thursday, MarketBeat reports. They presently have a $165.00 target price on the medical research company’s stock, down from their prior target price of $240.00. Barclays‘s price objective suggests a potential upside of 14.55% from the stock’s current price.

Several other analysts also recently commented on ICLR. William Blair restated an “outperform” rating on shares of ICON Public in a research note on Tuesday, January 14th. The Goldman Sachs Group cut ICON Public from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $250.00 to $200.00 in a research note on Friday, March 21st. Truist Financial lowered their target price on ICON Public from $262.00 to $208.00 and set a “buy” rating on the stock in a research report on Thursday. Mizuho cut their target price on ICON Public from $238.00 to $200.00 and set an “outperform” rating on the stock in a report on Wednesday. Finally, JPMorgan Chase & Co. decreased their price target on shares of ICON Public from $280.00 to $265.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd. Six investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $243.33.

ICON Public Trading Up 1.0 %

Shares of ICLR stock opened at $144.04 on Thursday. ICON Public has a fifty-two week low of $138.51 and a fifty-two week high of $347.72. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.34 and a current ratio of 1.26. The stock has a 50 day simple moving average of $179.62 and a two-hundred day simple moving average of $210.84. The company has a market cap of $11.63 billion, a P/E ratio of 15.11, a PEG ratio of 1.86 and a beta of 1.24.

ICON Public (NASDAQ:ICLR) last released its earnings results on Wednesday, February 19th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.41 by $0.01. The company had revenue of $2.04 billion for the quarter, compared to the consensus estimate of $2.04 billion. ICON Public had a net margin of 9.56% and a return on equity of 11.81%. Research analysts forecast that ICON Public will post 13.38 earnings per share for the current year.

Institutional Investors Weigh In On ICON Public

A number of institutional investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its stake in shares of ICON Public by 64.0% in the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock worth $91,000 after buying an additional 169 shares during the last quarter. Steph & Co. lifted its holdings in ICON Public by 3.7% during the fourth quarter. Steph & Co. now owns 1,560 shares of the medical research company’s stock worth $327,000 after acquiring an additional 55 shares during the period. Park Place Capital Corp grew its stake in ICON Public by 281.4% in the 4th quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 166 shares during the period. Avior Wealth Management LLC increased its position in shares of ICON Public by 76.0% during the 4th quarter. Avior Wealth Management LLC now owns 894 shares of the medical research company’s stock valued at $187,000 after purchasing an additional 386 shares during the last quarter. Finally, Tributary Capital Management LLC raised its stake in shares of ICON Public by 116.1% during the 4th quarter. Tributary Capital Management LLC now owns 3,950 shares of the medical research company’s stock worth $828,000 after purchasing an additional 2,122 shares during the period. 95.61% of the stock is owned by institutional investors.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.